Galena (GALE) soars 17.2% after signing a deal with Teva (TEVA) for the commercialization of its NeuVax breast cancer treatment in Israel. While financial terms weren't disclosed, Teva will make significant royalty payments to Galena on future sales. Israel will be the location of at least four sites for Phase 3 trials of NeuVax.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at CNBC.com (May 21, 2014)
at CNBC.com (Apr 8, 2014)
at CNBC.com (Mar 17, 2014)
at MarketWatch.com (Mar 17, 2014)
at CNBC.com (Jan 16, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs